Journal of radiological science and technology (대한방사선기술학회지:방사선기술과학)

Korean Society of Radiological Science (대한방사선과학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Caregivers' Exposed Dose and Patients' External Dose Rate for Radioactive Iodine (I-131) Therapy Administration in Isolated Ward

방사성요오드(I-131) 격리병실 치료 관리를 위한 환자의 체외방사선량률과 상주 보호자의 피폭선량평가

  • Kang, Seok-Jin (Department of Convergent Medical Physics, Graduate School of Engineering, Konkuk University) ;
  • Lee, Doo-Hyeon (Department of Convergent Medical Physics, Graduate School of Engineering, Konkuk University) ;
  • So, Young (Department of Convergent Medical Physics, Graduate School of Engineering, Konkuk University) ;
  • Lee, Jeong-Woo (Department of Convergent Medical Physics, Graduate School of Engineering, Konkuk University)
  • 강석진 (건국대학교 산업대학원 의학물리융합학과) ;
  • 이두현 (건국대학교 산업대학원 의학물리융합학과) ;
  • 소영 (건국대학교 산업대학원 의학물리융합학과) ;
  • 이정우 (건국대학교 산업대학원 의학물리융합학과)
  • Received : 2022.06.14
  • Accepted : 2022.08.10
  • Published : 2022.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

In this study, the radiation dose rate was measured by time and distance and evaluated whether radiation dose rate was suitable for domestic and international discharge criteria. In addition, the radiation dose emitted from the patient was measured with a glass dosimeter to evaluate the exposure dose if the caregiver stays in the isolated ward by placing a humanoid phantom instead of the caregiver at a distance of 1 m from the patient, on the second day of treatment. After 23 hours of isolation, the radiation dose rates at a distance of 1 m were 20.54 ± 6.21 µSv/h at 2.96 GBq administration and 27.94 ± 12.33 µSv/h at 3.70 GBq administration. The radiation dose rates at a distance of 1 m were 25.90 ± 2.21 µSv/h when 2.96 GBq was administered and 34.22 ± 10.06 µSv/h when 3.70 GBq was administered after 18 hours of isolation. However, if the isolation period is short may cause unnecessary radiation exposure to the third person. The reading of the attached dosimeter from the morning of the second day of treatment until removal was 0.01 to 0.95 mSv, which is a surface dose determined by the International Commission on Radiation Units and Measurements. And the depth dose was 0.01 to 0.99 mSv. On the second day of treatment, even if the patient caregivers stayed in the isolation ward, the exposure dose of the patient family did not exceed the effective dose limit of 5 mSv recommended by the ICRP and NCRP.

Keywords

References

  1. Baek SM, Ko SJ, Kim CS, Kim JH, Kang SS. A Study on Ways to Optimize the Period of Hospitaliztion During High-Dose I-131 Treatment of the Thyroid Cancer. Journal of Radiological Science and Technology. 2010;33(3):269-76.
  2. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: Literature review of utility, dose, and toxicity. European Thyroid Journal. 2017;6(4):187-96. https://doi.org/10.1159/000468927
  3. Lahfi Y, Anjak O. Evaluation of the release criteria from hospital of thyroid carcinoma patient treated with 131I. Radiation Protection Dosimetry. 2016;(4):534-8.
  4. Abu-Khaled Y, Sandouqa A, Haddadin I. Radiation exposure from radioactive iodine I-131 in and surrounding the patients' room. Radiation Protection Dosimetry. 2009;135(1):64-8. https://doi.org/10.1093/rpd/ncp093
  5. Agency IAE. Release of Patients After Radionuclide Therapy, with Contributions from the International Commission on Radiological Protection. International Atomic Energy Agency; 2009.
  6. Radioactivity MSC-oPitMoPWHRTAo. Management of radionuclide therapy patients. NCRP; 2007.
  7. Howe DB, Beardsley M, Bakhsh S. Consolidated guidance about materials licenses. Program-Specific Guidance About Medical Use Licenses (NUREG-1556, volume 9, revision 2); 2008.
  8. Nuclear Safety Commission No. 19 Regulations on Technical Standards such as Radiation Safety Management. Nuclear Safety Commission Notification No. 2015-5 Technical Standards on Radiation Safety Management in the Medical Sector.
  9. Jeong GH, Lee HK, Cho WK, Lee JK. Caregiver or Family Doses due to Discharged I-131 Administrated Patient from the Hospital. Journal of Radiological Science and Technology. 2010;33(2):149-54.
  10. Valentin J, Boice Jr. J, Clarke R, Cousins C, Gonzalez A, Lee J, et al. Published on behalf of International Commission on Radiological Protection. ICRP Publication; 2007.
  11. Schneider S, McGuire SA, Behling U, Behling K, Goldin D. Regulatory analysis on criteria for the release of patients administered radioactive material. Nuclear Regulatory Commission; 1994.
  12. Kadhim AA, Sheikhzadeh P, Farzanefar S, Yavari S, Ay MR. Radiation Dose Assessment to Family Members Taking Care of Non-Cancerous Thyroid Patients Treated with I-131 Therapy in Nuclear Medicine Department. Radiation Protection Dosimetry. 2020;190(2):208-16. https://doi.org/10.1093/rpd/ncaa092
  13. Ebrahimi M, Changizi V, Kardan MR, Pooya SMH, Geramifar P. Experimental and analytical dose assessment of patient's family members treated with I-131. Phys Med. 2016;3(32):292.
  14. Moon YM. A study on the effective dose measurement for cone beam computed tomography using glass dosimeter. Graduate School, Dong-A University; 2013.
  15. Kang IS, Ahn SM. Evaluation of Usability and Radiation Dose Measurement Using Personal Radiation Exposure Dosimeter. International Journal of Contents. 2014;14(11):864-870.
  16. Taghavaee S, Kasesaz Y, Barough MS. Analysis of the caregiver effective dose during I-131 therapy of thyroid. Journal of Cancer Research and Therapeutics. 2018;14(6):1361.
  17. Director M, Chief B, Director A, Date S, Date A. Office of Federal and State Materials and Environmental Management Programs (FSME) Procedure Approval Reviewing the Non-Common Performance Indicator. Uranium Recovery Program-SA-110; 2009.
  18. De Carvalho JWdA, Sapienza M, Ono C, Watanabe T, Guimaraes MI, Gutterres R, et al. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (I-131) Nal, on an outpatient basis, be safe? Nuclear Medicine Communications. 2009;30(7):533-41. https://doi.org/10.1097/MNM.0b013e32832b79bc
  19. Park SG. Effective half-life of I-131 in patients with differentiated thyroid cancer treated by radioactive I-131. Nuclear Medicine and Molecular Imaging. 2008;42(6):464-8.
  20. Gringsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactiveiodine (I-131) therapy for thyroid carcinoma. Jama. 2000;283(17):2272-4. https://doi.org/10.1001/jama.283.17.2272
  21. Marriott CJ, Webber CE, Gulenchyn KY. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy. Radiation Protection Dosimetry. 2017;123(1):62-7. https://doi.org/10.1093/rpd/ncl084
  22. Commission UNR. Release of individuals containing unsealed byproduct material or implants containing byproduct material. Washington, DC: US Nuclear Regulatory Commission.10; 2017.
  23. Hennessey JV, Parker JA, Kennedy R, Garber JR. Comments regarding Practice Recommendations of the American Thyroid Association for radiation safety in the treatment of thyroid disease with radioiodine. Thyroid. 2012;22(3):336-7. https://doi.org/10.1089/thy.2011.0378
  24. Sisson TATATRSJC, Freitas J, McDougall IR, Dauer LT, Hurley JR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: Practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335-46. https://doi.org/10.1089/thy.2010.0403